Health Prob Civil.
1. McCarthy GT, West CM. Ablepheron Macrostomia Syndrome. Dev Med Child Neurol. 1977; 19(5): 659-63. https://doi.org/10.1111/j.1469-8749.1977.tb07999.x
2.
De Maria B, Mazzanti L, Roche N, Hennekam RC. Barber-Say Syndrome and Ablepharon-Macrostomia syndrome: an overview. Am J Med Genet A. 2016; 170(8): 1989-2001. https://doi.org/10.1002/ajmg.a.37757
3.
AMS. Hereditary Ocular Diseases [Internet]. AMS [access 2024 Apr 17]. Available from: https://disorders.eyes.arizona.edu/category/alternate-names/ams
4.
Alexopoulos D, Matchinski TL. A case of ablepharon macrostomia syndrome requiring multidisciplinary care. Clin Exp Optom. 2021; 104(4): 541-543. https://doi.org/10.1080/08164622.2021.1878839
5.
Nwaneli E, Chukwuka J, Uju C, Epundu C. Ablepharon Macrostomia Syndrome: absent prepuce in the first case report in West Africa. Niger Postgrad Med J. 2021; 28(4): 298. https://doi.org/10.4103/npmj.npmj_318_20
6.
Price NJ, Pugh RE, Farndon PA, Willshaw HE. Ablepharon Macrostomia Syndrome. Br J Ophthalmol. 1991; 75(5): 317-319. https://doi.org/10.1136/bjo.75.5.317
7.
Gupta SP, Saxena RC. CRYPTOPHTHALMOS. Br J Ophthalmol. 1962; 46(10): 629-32. https://doi.org/10.1136/bjo.46.10.629
8.
Cruz AA, Souza CA, Ferraz VE, Monteiro CA, Martins FA. Familial occurrence of ablepharon macrostomia syndrome: eyelid structure and surgical considerations. Arch Ophthalmol Chic Ill 1960. 2000; 118(3): 428-30.
9.
Ferraz VE, Melo DG, Hansing SE, Cruz AA, Pina-Neto JM. Ablepharon-Macrostomia syndrome: first report of familial occurrence. Am J Med Genet. 2000; 94(4): 281-283. https://doi.org/10.1002/1096-8628(20001002)94:4<281::AID-AJMG3>3.0.CO;2-S
10.
Rohena L, Kuehn D, Marchegiani S, Higginson JD. Evidence for autosomal dominant inheritance of Ablepharon-Macrostomia Syndrome. Am J Med Genet A. 2011; 155A(4): 850-4. https://doi.org/10.1002/ajmg.a.33900
11.
Marchegiani S, Davis T, Tessadori F, van Haaften G, Brancati F, Hoischen A, et al. Recurrent mutations in the basic domain of TWIST2 cause Ablepharon Macrostomia and Barber-Say Syndromes. Am J Hum Genet. 2015; 97(1): 99–110. https://doi.org/10.1016/j.ajhg.2015.05.017
12.
https://pubchem.ncbi.nlm.nih.gov [Internet]. TWIST2 – twist family bHLH transcription factor 2 (human) [access 2024 Jul 30]. Available from: https://pubchem.ncbi.nlm.nih.gov/gene/TWIST2/human
13.
Zeng W, Gu S, Yu Y, Feng Y, Xiao M, Feng XH. ZNF451 stabilizes TWIST2 through SUMOylation and promotes epithelial-mesenchymal transition. Am J Cancer Res. 2021; 11(3): 898–915.
14.
Jacob T, Chakravarty A, Panchal A, Patil M, Ghodadra G, Sudhakaran J, et al. Zebrafish twist2/dermo1 regulates scale shape and scale organization during skin development and regeneration. Cells Dev. 2021; 166: 203684. https://doi.org/10.1016/j.cdev.2021.203684
15.
Li Y, Wang W, Wang W, Yang R, Wang T, Su T, et al. Correlation of TWIST2 up-regulation and epithelial-mesenchymal transition during tumorigenesis and progression of cervical carcinoma. Gynecol Oncol. 2012; 124(1): 112–8. https://doi.org/10.1016/j.ygyno.2011.09.003
16.
Chang AT, Liu Y, Ayyanathan K, Benner C, Jiang Y, Prokop JW, et al. An evolutionarily conserved DNA architecture determines target specificity of the TWIST family bHLH transcription factors. Genes Dev. 2015; 29(6): 603–16. https://doi.org/10.1101/gad.242842.114
17.
Haensel J, Kohlschmidt N, Pitz S, Keilmann A, Zenker M, Ullmann R, et al. Case report supporting that the Barber-Say and Ablepharon Macrostomia Syndromes could represent one disorder. Am J Med Genet A. 2009; 149A(10): 2236–40. https://doi.org/10.1002/ajmg.a.32993
18.
De Niear MA, Law JJ, Abel TW, Mawn LA. Ocular adnexal phenotype and management of a patient with mosaic expression of a mutation in TWIST2. Orbit. 2022; 41(6): 779–82. https://doi.org/10.1080/01676830.2021.1930066
19.
Zhao Y, Shang D, Ying R, Cheng H, Zhou R. An optimized base editor with efficient C-to-T base editing in zebrafish. BMC Biol. 2020; 18(1): 190. https://doi.org/10.1186/s12915-020-00923-z
20.
Lee BH, Aggarwal A, Slavotinek A, Edelmann L, Chen B, Desnick RJ. The focal facial dermal dysplasias: phenotypic spectrum and molecular genetic heterogeneity. J Med Genet. 2017; 54(9):585–90. https://doi.org/10.1136/jmedgenet-2017-104561
21.
Ayaz A, Yalcintepe S, Ozalp Yuregir O, Sahin Y, Ozer A, Eser M, et al. The TWIST2 mutation causes Setleis syndrome: a rare clinical case report. Clin Dysmorphol. 2017; 26(2): 128–31. https://doi.org/10.1097/MCD.0000000000000156
22.
Tukel T, Šošić D, Al-Gazali LI, Erazo M, Casasnovas J, Franco HL, et al. Homozygous nonsense mutations in TWIST2 cause Setleis Syndrome. Am J Hum Genet. 2010; 87(2): 289–96. https://doi.org/10.1016/j.ajhg.2010.07.009
23.
Franco HL, Casasnovas JJ, Leon RG, Friesel R, Ge Y, Desnick RJ, et al. Nonsense mutations of the bHLH transcription factor TWIST2 found in Setleis Syndrome patients cause dysregulation of periostin. Int J Biochem Cell Biol. 2011; 43(10): 1523–31. https://doi.org/10.1016/j.biocel.2011.07.003
24.
Crespo NE, Torres-Bracero A, Renta JY, Desnick RJ, Cadilla CL. Expression profiling identifies TWIST2 target genes in setleis syndrome patient fibroblast and lymphoblast cells. Int J Environ Res Public Health. 2021; 18(4): 1997. https://doi.org/10.3390/ijerph18041997
25.
Weaver DD, Norby AR, Rosenfeld JA, Proud VK, Spangler BE, Ming JE, et al. Chromosome 1p36.22p36.21 duplications/triplication causes Setleis syndrome (focal facial dermal dysplasia type III). Am J Med Genet A. 2015; 167(5): 1061–70. https://doi.org/10.1002/ajmg.a.36973
26.
Lee BH, Kasparis C, Chen B, Mei H, Edelmann L, Moss C, et al. Setleis syndrome due to inheritance of the 1p36.22p36.21 duplication: evidence for lack of penetrance. J Hum Genet. 2015; 60(11): 717–22. https://doi.org/10.1038/jhg.2015.103
27.
Oh RY, Chun K, Kowalski PE, Chitayat D. De novo triplication at 1p36.23p36.22 further refines the dosage sensitive region of overlap in Setleis syndrome (focal facial dermal dysplasia type III). Am J Med Genet A. 2023; 191(6): 1607–13. https://doi.org/10.1002/ajmg.a.63175
28.
Lee BH, Morice-Picard F, Boralevi F, Chen B, Desnick RJ. Focal facial dermal dysplasia type 4: identification of novel CYP26C1 mutations in unrelated patients. J Hum Genet. 2018; 63(3): 257–61. https://doi.org/10.1038/s10038-017-0375-x
29.
Slavotinek AM, Mehrotra P, Nazarenko I, Tang PLF, Lao R, Cameron D, et al. Focal facial dermal dysplasia, type IV, is caused by mutations in CYP26C1. Hum Mol Genet. 2013; 22(4): 696–703. https://doi.org/10.1093/hmg/dds477
30.
Çepni E, Börklü E, Avcı Ş, Kalaycı T, Eraslan S, Kayserili H. Revisiting TOP2B – related phenotypes: three new cases and literature review. Clin Genet. 2023; 104(2): 251–8. https://doi.org/10.1111/cge.14341
31.
Kallish S, McDonald‐McGinn DM, Van Haelst MM, Bartlett SP, Katowitz JA, Zackai EH. Ablepharon–Macrostomia Syndrome – extension of the phenotype. Am J Med Genet A. 2011; 155(12): 3060–2. https://doi.org/10.1002/ajmg.a.34287
32.
Broderick L, Yost S, Li D, McGeough MD, Booshehri LM, Guaderrama M, et al. Mutations in topoisomerase IIβ result in a B cell immunodeficiency. Nat Commun. 2019; 10(1): 3644. https://doi.org/10.1038/s41467-019-11570-6
33.
Takenouchi T, Sakamoto Y, Sato H, Suzuki H, Uehara T, Ohsone Y, et al. Ablepharon and craniosynostosis in a patient with a localized TWIST1 basic domain substitution. Am J Med Genet A. 2018; 176(12): 2777–80. https://doi.org/10.1002/ajmg.a.40525
34.
Kim S, Twigg SRF, Scanlon VA, Chandra A, Hansen TJ, Alsubait A, et al. Localized TWIST1 and TWIST2 basic domain substitutions cause four distinct human diseases that can be modeled in Caenorhabditis elegans. Hum Mol Genet. 2017; 26(11): 2118-32. https://doi.org/10.1093/hmg/ddx107
35.
Stevens CA, Sargent LA. Ablepharon-macrostomia syndrome. Am J Med Genet. 2002; 107(1): 30-7. https://doi.org/10.1002/ajmg.10123
36.
Larumbe J, Villalta P, Velez I. Clinical variant of Ablepharon Macrostomia Syndrome. Case Rep Dermatol Med. 2011; 2011: 593045. https://doi.org/10.1155/2011/593045
37.
Brancati F, Mingarelli R, Sarkozy A, Dallapiccola B. Ablepharon-Macrostomia Syndrome in a 46-year-old woman. Am J Med Genet A. 2004; 127A(1): 96–8. https://doi.org/10.1002/ajmg.a.20658
38.
Feinstein E, Traish AS, Aakalu V, Kassem IS. A case report of Ablepharon-Macrostomia Syndrome with amniotic membrane grafting. Case Rep Ophthalmol. 2015; 6(3): 366–72. https://doi.org/10.1159/000441615
39.
Hornblass A, Reifler DM. Ablepharon Macrostomia Syndrome. Am J Ophthalmol. 1985; 99(5): 552–6. https://doi.org/10.1016/S0002-9394(14)77956-5
40.
Cesarino EJ, Pinheiro M, Freire‐Maia N, Meira‐Silva MC, Opitz JM, Reynolds JF. Lid agenesis‐macrostomia‐psychomotor retardation‐forehead hypertrichosis – a new syndrome?. Am J Med Genet. 1988; 31(2): 299–304. https://doi.org/10.1002/ajmg.1320310207
41.
Ciriaco P, Carretta A, Negri G. Laryngo-tracheal stenosis in a woman with Ablepharon Macrostomia Syndrome. BMC Pulm Med. 2019; 19(1): 163. https://doi.org/10.1186/s12890-019-0921-8
42.
Hollanders K, Casteels I, Vandelanotte S, Reyniers R, Segers K, Nevens T, et al. Use of the masquerade flap in Ablepharon-Macrostomia Syndrome: a case report. Cornea. 2018; 37(7): 929–32. https://doi.org/10.1097/ICO.0000000000001563
43.
De Maria B, de Jager T, Sarubbi C, Bartsch O, Bianchi A, Brancati F, et al. Barber-Say Syndrome and Ablepharon-Macrostomia Syndrome: a patient’s view. Mol Syndromol. 2017; 8(4): 172–8. https://doi.org/10.1159/000472408
44.
Cruz AAV, Quiroz D, Boza T, Wambier SPF, Akaishi PS. Long-term results of the surgical management of the upper eyelids in “Ablepharon”-Macrostomia Syndrome. Ophthal Plast Reconstr Surg. 2020; 36(1):21–5. https://doi.org/10.1097/IOP.0000000000001442
45.
Umfress A. Ablepharon Macrostomia Syndrome [Internet]. 2024 [access 17.04.2024. Available from: https://eyewiki.org/Ablepharon_Macrostomia_Syndrome#cite_note-14
46.
Genetic and Rare Diseases Information Center. Ablepharon Macrostomia Syndrome [Internet]. 2024 [access 17.04.2024.. Available from: https://rarediseases.info.nih.gov/diseases/3/ablepharon-macrostomia-syndrome
47.
Schanze D, Harakalova M, Stevens CA, Brancati F, Dallapiccola B, Farndon P, et al. Ablepharon Macrostomia Syndrome: a distinct genetic entity clinically related to the group of FRAS-FREM complex disorders. Am J Med Genet A. 2013; 161A(12): 3012-7. https://doi.org/10.1002/ajmg.a.36119
48.
Cavalcanti DP, Matejas V, Luquetti D, Mello MF, Zenker M. Fraser and Ablepharon macrostomia phenotypes: concurrence in one family and association with mutated FRAS1. Am J Med Genet A. 2007; 143A(3): 241-247. https://doi.org/10.1002/ajmg.a.31426
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
